Medical Condition News

RSS

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

IRIDEX Corporation today announced approval and commercial availability in Japan for its extended family of EndoProbe laser delivery devices. The EndoProbe is an intraocular laser delivery device used during vitreoretinal surgery for the treatment of multiple disorders including: diabetic retinopathy, retinal detachments and vitreous hemorrhage. IRIDEX distributes products in Japan through their partner, TOMEY Corporation.

5 Oct 2010

Caring.com introduces interactive Alzheimer’s resource for caregivers

Caring.com today launched Steps & Stages, the first-ever interactive guide, support system, and customized e-mail newsletter that delivers specific, stage-appropriate advice for those providing care for a loved one with Alzheimer's or another form of dementia.

5 Oct 2010

Majority of Canadians with asthma consider their disease 'well controlled'

A new survey, Asthma Insight and Management in Europe and Canada (EUCAN AIM), reveals that a majority of Canadians with asthma considered their disease "well controlled" at the time of the survey. However, in the year prior to the survey, more than half (52 per cent) required acute treatment for asthma, including seeing a doctor for worsening symptoms (45 per cent), unscheduled emergency room visits (28 per cent), and being hospitalized overnight (five per cent).

5 Oct 2010

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone for the treatment of growth hormone deficiency.

5 Oct 2010

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

Intellect Neurosciences, Inc., a biopharmaceutical company with internal preclinical and clinical-stage pipelines, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a patent from the United States Patent and Trademark Office (USPTO) related to its internal Alzheimer's disease (AD) monoclonal antibody program.

5 Oct 2010

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

ImmunoCellular Therapeutics, a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that the company's clinical data from ICT-107 will be featured in two oral sessions at the World Stem Cell Summit, which is being held October 4-6 in Detroit, MI.

5 Oct 2010

Dr. Bessler joins Children's Hospital of Philadelphia

One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia. Hematology researcher Monica Bessler, M.D., Ph.D., arrived at the hospital this summer to establish a new program, the Pediatric and Adult Comprehensive Bone Marrow Failure Center.

5 Oct 2010

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

This study demonstrates that supplemental brief dynamic therapy in the treatment of patients with obsessive compulsive-disorder with concurrent major depressive disorder (who are receiving effective medication) has no significant clinical effect on both obsessive and depressive symptoms.

5 Oct 2010

AACR to host special conference on colorectal cancer

This October, the American Association for Cancer Research will host the special conference Colorectal Cancer: Biology to Therapy at the Loews Philadelphia Hotel. Hundreds of scientists, physicians and allied health professionals will gather and discuss new data on new screening methods and emerging therapies.

5 Oct 2010

GPs less successful in identifying depression in older people

Depression in the elderly is frequently unrecognized by physicians. This study attempts to understand why. Studies that examined the unassisted (clinical) ability of general practitioners (GPs; primary care physicians) to identify depression were divided into those of older adults, younger adults and mixed populations.

5 Oct 2010

Department of Defense awards Banyan Biomarkers $26.3M contract to develop diagnostic test for TBI

Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), announced today that they have been awarded a $26.3 Million Contract for the development of a diagnostic test for TBI.

5 Oct 2010

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Thirteen national and international experts in the field of Brain Stimulation in Psychiatry and Neurology will meet October 7 and 8 during a conference held at the Douglas Mental Health University Institute. They will present research findings and ground-breaking clinical applications concerning the use of brain stimulation techniques. New treatments still under development, such as transcranial magnetic stimulation, will also be discussed. Close to 150 participants are expected to take part in this conference.

5 Oct 2010

Nursing staff have 'difficulty' detecting depression and distress in patients: Study

New research from the University of Leicester reveals that nursing staff have 'considerable difficulty' detecting depression and distress in patients.

5 Oct 2010

Telemedicine helps in early diagnosis and treatment of pediatric heart problems

A new study by researchers from Children's Mercy Hospitals and Clinics in Kansas City, Mo., found that rapid electronic review of children's heart images by specialists nearly 200 miles away allowed for earlier diagnosis and treatment of potentially serious pediatric heart problems. The study was presented at the American Academy of Pediatrics National Conference and Exhibition in San Francisco.

5 Oct 2010

Study: 18% of children with ADHD suffered from depression as adolescents

Children diagnosed with attention deficit/hyperactivity disorder (ADHD) at ages 4 to 6 are more likely to suffer from depression as adolescents than those who did not have ADHD at that age, according to a long-term study published in the October issue of the Archives of General Psychiatry. Although it was an uncommon occurrence, the children with ADHD also were somewhat more likely to think about or attempt suicide as adolescents.

5 Oct 2010

Scientists use directed light to cause arrhythmia in genetically modified mice

Scientists at the University of Bonn have altered cardiac muscle cells to make them controllable with light. They were thus able to use directed light to cause conditions such as arrhythmia in genetically modified mice. The method opens up completely new possibilities for researching the development of such arrhythmias. The study will be published in the upcoming edition of "Nature Methods".

5 Oct 2010

Neuraltus achieves last patient out for NP001, NP002 studies

Neuraltus Pharmaceuticals, a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases, announced today the Company has achieved last patient out in two studies: a Phase 1 clinical study of NP001 in patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease) and a Phase 1/2 clinical study of NP002 in patients with L-dopa-induced dyskinesias (muscle movement disorders).

5 Oct 2010

Merck Serono to present Erbitux data at ESMO Congress

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.

5 Oct 2010

RHUCIN clinical trial results published in JACI journal

Santarus, Inc., a specialty biopharmaceutical company, today announced the publication of an integrated analysis of two randomized placebo-controlled clinical trials with RHUCIN (recombinant human C1 inhibitor, or rhC1INH), in the October issue of the peer reviewed Journal of Allergy and Clinical Immunology (JACI).

5 Oct 2010

Research on T cell may lead to new treatment options for type 1 diabetes

A research team from the University of British Columbia and the Child & Family Research Institute (CFRI) at BC Children's Hospital has identified the role of a type of T cell in type 1 diabetes that may lead to new treatment options for young patients.

5 Oct 2010

Medical Condition News

IRIDEX announces commercial availability of extended EndoProbe laser delivery device family in Japan

Caring.com introduces interactive Alzheimer’s resource for caregivers

Majority of Canadians with asthma consider their disease 'well controlled'

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

Intellect Neurosciences receives patent for Alzheimer's disease monoclonal antibody program

ImmunoCellular Therapeutics to present ICT-107 clinical data at World Stem Cell Summit

Dr. Bessler joins Children's Hospital of Philadelphia

Supplemental brief dynamic therapy does not benefit patients with obsessive-compulsive disorder: Study

AACR to host special conference on colorectal cancer

GPs less successful in identifying depression in older people

Department of Defense awards Banyan Biomarkers $26.3M contract to develop diagnostic test for TBI

International conference on brain stimulation in psychiatry and neurology to be held October 7 and 8

Nursing staff have 'difficulty' detecting depression and distress in patients: Study

Telemedicine helps in early diagnosis and treatment of pediatric heart problems

Study: 18% of children with ADHD suffered from depression as adolescents

Scientists use directed light to cause arrhythmia in genetically modified mice

Neuraltus achieves last patient out for NP001, NP002 studies

Merck Serono to present Erbitux data at ESMO Congress

RHUCIN clinical trial results published in JACI journal

Research on T cell may lead to new treatment options for type 1 diabetes

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News